Emerson Electric
EMR
$147.94
+2.10%
Emerson Electric Co. is a global industrial automation leader that designs and manufactures automation software, valves, gauges, switches, and power tools for factory and process automation. Through a history of strategic acquisitions, Emerson has transformed into a pure-play industrial automation company, competing as a market leader in the fragmented automation space. The current investor narrative centers on Emerson's ability to sustain mid-single-digit organic growth amid mixed industrial end-market demand, while margin expansion from its software and systems segment and disciplined capital allocation drive earnings momentum. Recent quarterly results showed 2.9% revenue growth, with the market closely watching order trends and the pace of automation adoption across manufacturing verticals.…
EMR
Emerson Electric
$147.94
Investment Opinion: Should I buy EMR Today?
Rating: Hold. Emerson's strong margins and free cash flow are offset by decelerating growth and a high trailing P/E. The consensus analyst rating is Buy with an average target of $163.76, but the stock's recent underperformance and growth slowdown warrant caution.
Supporting Evidence: The forward P/E of 19.4x is below the sector average of 22x, suggesting reasonable value on expected earnings. Revenue growth of 2.9% YoY is positive but decelerating, while gross margin of 53.1% and operating margin of 19.8% are well above industry norms. TTM free cash flow of $3.115 billion provides a 4.2% yield, and the company has a strong history of returning capital via dividends and buybacks. However, the trailing P/E of 32.2x is elevated, and the stock has underperformed the market by 21.7% over the past year.
Risks & Conditions: The biggest risks are further revenue deceleration and multiple compression. This Hold would upgrade to Buy if revenue growth reaccelerates above 5% or if the trailing P/E compresses below 25x. It would downgrade to Sell if revenue growth turns negative or if the stock breaks below the 52-week low of $122.64. Overall, Emerson appears fairly valued relative to its history and peers, with the forward P/E suggesting modest upside but the trailing P/E indicating caution.
Sign up to view all
EMR 12-Month Price Forecast
Emerson's outlook is balanced between the risk of further growth deceleration and the support from a reasonable forward valuation. The base case of stable growth and steady margins is most likely, but the wide range of analyst targets reflects high uncertainty. The neutral stance is justified by the conflicting signals: strong margins and cash flow versus decelerating revenue and market underperformance. An upgrade to bullish would require evidence of reaccelerating growth, while a downgrade to bearish would follow a break below the 52-week low.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Emerson Electric's 12-month outlook, with a consensus price target around $163.54 and implied upside of +10.5% versus the current price.
Average Target
$163.54
0 analysts
Implied Upside
+10.5%
vs. current price
Analyst Count
—
covering this stock
Price Range
$104 - $203
Analyst target range
Emerson is covered by 27 analysts, with a consensus recommendation of 'Buy' (mean rating 1.9 on a 1–5 scale). The average price target is $163.76, implying approximately 17.4% upside from the current price of $139.54. The distribution leans bullish, with 16 buys, 9 holds, and 2 sells, reflecting broad confidence in the company's strategic pivot to automation. The target range spans from a low of $104.00 to a high of $203.00, indicating significant uncertainty about the pace of earnings recovery. The high target of $203 assumes a successful acceleration in software revenue and margin expansion, while the low target of $104 prices in a prolonged industrial downturn or execution missteps. Recent rating actions show stability: Wells Fargo and Barclays maintain Equal Weight, while RBC Capital and Evercore ISI reiterate Outperform. Notably, Deutsche Bank downgraded from Buy to Hold in February 2026, suggesting some caution on near-term headwinds. The wide spread between low and high targets (nearly 95% of the current price) underscores elevated uncertainty, but the consensus remains constructive.
Bulls vs Bears: EMR Investment Factors
Emerson presents a mixed picture: strong margins, robust free cash flow, and a forward valuation that appears reasonable against expected earnings growth support the bull case. However, decelerating revenue, a high trailing P/E, and persistent market underperformance are clear warning signs. The single most important tension is whether the company can reaccelerate organic growth to justify its premium valuation. If growth stabilizes or picks up, the stock could rerate higher; if it continues to slow, the stock may fall toward the lower end of analyst targets. Currently, the bearish evidence from price action and growth deceleration slightly outweighs the bullish fundamentals, but the forward valuation provides a margin of safety.
Bullish
- Strong Margin Expansion Trajectory: Gross margin improved to 53.1% in Q2 2026 from 52.8% a year earlier, and operating margin held steady at 19.8%, well above the industrial sector average of ~15%. This demonstrates pricing power and a favorable mix shift toward higher-margin software revenue.
- Significant Upside to Analyst Targets: The average analyst price target is $163.76, implying 17.4% upside from the current price of $139.54. With 27 analysts covering the stock and a consensus Buy rating, the market expects meaningful earnings growth ahead.
- Healthy Free Cash Flow Generation: TTM free cash flow stands at $3.115 billion, supporting a FCF yield of approximately 4.2%. This cash generation funds dividends ($312 million in Q2) and share repurchases ($292 million), providing a strong capital return to shareholders.
- Attractive Forward Valuation: The forward P/E of 19.4x is below the sector average of 22x, suggesting the stock is undervalued relative to expected earnings growth. The PEG ratio of 1.78 indicates the stock is fairly valued given its growth prospects.
Bearish
- Decelerating Revenue Growth: Revenue growth slowed to 2.9% YoY in Q2 2026 from 4.4% in Q1 2026, indicating a softening demand environment. This deceleration raises concerns about the sustainability of the automation cycle and the company's ability to maintain mid-single-digit organic growth.
- High Trailing P/E Premium: The trailing P/E of 32.2x is 46% above the industrial sector average of 22x, leaving little room for error. If earnings fail to meet elevated expectations, the stock could face multiple compression.
- Significant Underperformance vs. Market: EMR has underperformed the S&P 500 by 21.7% over the past year, with a 1-year price change of -3.4% versus SPY's +18.4%. This persistent relative weakness suggests structural headwinds beyond market sentiment.
- Wide Analyst Target Range: Analyst targets range from $104 to $203, a spread of nearly 95% of the current price. This extreme dispersion reflects high uncertainty about the pace of earnings recovery and the risk of a prolonged industrial downturn.
EMR Technical Analysis
Emerson's 1-year price change of -3.4% masks a volatile trajectory, with the stock currently at $139.54, representing 84.5% of its 52-week range ($122.64–$165.15). The stock is in a short-term downtrend after failing to hold above $150, but remains above the 52-week low, suggesting a potential basing pattern rather than a full-blown bear market. The 1-year relative strength vs. SPY of -21.7% confirms significant underperformance versus the broader market, which has rallied 18.4% over the same period. Over the past 3 months, EMR has declined 4.7%, while the S&P 500 gained 4.7%, widening the relative underperformance gap. The 1-month price change of -6.3% versus SPY's +0.3% indicates accelerating downside momentum, with the stock breaking below its 50-day moving average in late June. This short-term weakness diverges from the 1-year trend, which is only slightly negative, suggesting the pullback may be a mean-reversion opportunity if support holds. The 52-week low of $122.64 provides a clear support level, while resistance sits at the 52-week high of $165.15. A break above $165 would signal a resumption of the long-term uptrend, while a drop below $122.64 could trigger further selling. With a beta of 1.24, Emerson is 24% more volatile than the market, meaning the stock amplifies both upside and downside moves, requiring careful risk management.
Beta
1.24
1.24x market volatility
Max Drawdown
-23.7%
Largest decline past year
52-Week Range
$123-$165
Price range past year
Annual Return
+0.8%
Cumulative gain past year
| Period | EMR Return | S&P 500 |
|---|---|---|
| 1m | +4.6% | +0.8% |
| 3m | +4.7% | +3.5% |
| 6m | +0.2% | +7.2% |
| 1y | +0.8% | +16.5% |
| ytd | +8.9% | +8.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
EMR Fundamental Analysis
Revenue in the most recent quarter (Q2 2026) was $4.562 billion, up 2.9% year-over-year, but decelerating from the 4.4% growth seen in Q1 2026. The trailing twelve-month revenue stands at approximately $18.3 billion, with growth driven by the Software and Systems segment ($1.503 billion) and Intelligent Devices ($2.512 billion), while Safety and Productivity ($0.547 billion) remains a smaller contributor. The growth trajectory has moderated from double-digit rates in fiscal 2022–2023, reflecting a normalization in industrial demand, but the shift toward higher-margin software revenue supports the investment thesis. Net income for Q2 2026 was $618 million, with diluted EPS of $1.10, up from $0.86 in the year-ago quarter, demonstrating strong operating leverage. Gross margin improved to 53.1% from 52.8% a year earlier, while operating margin held steady at 19.8%, both above the industrial sector average of ~15%. The net margin of 13.5% is healthy and has been expanding over the past four quarters, driven by cost controls and a favorable mix shift toward software. Emerson's balance sheet is solid, with a debt-to-equity ratio of 0.68 and a current ratio of 0.88, indicating adequate liquidity. Free cash flow for the quarter was $694 million, bringing TTM FCF to $3.115 billion, which supports a FCF yield of approximately 4.2%. ROE stands at 11.3%, reflecting efficient capital use, while the company continues to return cash to shareholders via dividends ($312 million in Q2) and share repurchases ($292 million).
Quarterly Revenue
$4.6B
2026-03
Revenue YoY Growth
+2.9%
YoY Comparison
Gross Margin
53.1%
Latest Quarter
Free Cash Flow
$3.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is EMR Overvalued?
Since net income is positive, the primary valuation metric is the P/E ratio. Emerson's trailing P/E is 32.2x, while the forward P/E is 19.4x, implying the market expects significant earnings growth in the next year. The gap between trailing and forward P/E suggests that analysts anticipate a sharp rebound in EPS, likely driven by margin expansion and cost synergies. Compared to the industrial machinery sector average P/E of approximately 22x, Emerson trades at a 46% premium on a trailing basis, but only a 12% discount on a forward basis, indicating that the market is pricing in above-average growth. The PEG ratio of 1.78 suggests the stock is fairly valued relative to its expected earnings growth rate. Historically, Emerson's trailing P/E has ranged from 15x to 46x over the past five years, with the current 32.2x near the midpoint of that range. This is below the peak of 46x seen in mid-2024 but above the trough of 15x in late 2022. The current valuation implies that the market expects a recovery in earnings, but not an overly optimistic scenario, leaving room for upside if growth accelerates.
PE
32.2x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 16x~47x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
17.8x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Emerson's debt-to-equity ratio of 0.68 is manageable, but the current ratio of 0.88 indicates that current liabilities exceed current assets, posing a liquidity risk in a downturn. The company's net margin of 13.5% is healthy, but the deceleration in revenue growth from 4.4% to 2.9% YoY suggests that top-line momentum is fading. If this trend continues, the high trailing P/E of 32.2x could compress, leading to significant downside. Additionally, the company's reliance on acquisitions for growth means integration risks are ever-present, and any misstep could weigh on earnings.
Market & Competitive Risks: Emerson trades at a trailing P/E of 32.2x, a 46% premium to the industrial sector average of 22x, making it vulnerable to valuation compression if growth disappoints. The stock's beta of 1.24 implies 24% higher volatility than the market, amplifying downside in a broad selloff. The company faces competitive pressure from other automation players like Rockwell Automation and Siemens, which could limit market share gains. The lack of recent news provides no clear catalyst, leaving the stock at the mercy of macro trends and quarterly earnings.
Worst-Case Scenario: In a prolonged industrial recession where revenue growth turns negative and margins contract, the stock could fall to the analyst low target of $104.00, representing a 25.5% decline from the current price of $139.54. This scenario would be triggered by a sharp drop in manufacturing activity, order cancellations, and a failure to achieve expected cost synergies. The 52-week low of $122.64 provides a nearer-term floor, but a break below that level could accelerate selling toward $104.
FAQ
The primary risk is further revenue deceleration, as growth slowed from 4.4% to 2.9% YoY in the latest quarter. If this trend continues, the high trailing P/E of 32.2x could compress, leading to significant downside. A second risk is macro sensitivity: with a beta of 1.24, the stock is 24% more volatile than the market, so a broad selloff would hit EMR harder. Third, the wide analyst target range ($104-$203) reflects high uncertainty, and any negative earnings surprise could trigger a sharp decline. Finally, the current ratio of 0.88 indicates that current liabilities exceed current assets, posing a liquidity risk in a downturn.
The 12-month forecast is mixed, with three scenarios: a bull case (25% probability) targeting $165-$203, driven by reaccelerating growth and margin expansion; a base case (50% probability) targeting $140-$165, with stable growth and steady margins; and a bear case (25% probability) targeting $104-$122, driven by a recession or execution missteps. The base case is most likely, with the stock trading near the average analyst target of $163.76. Key assumptions include stable industrial demand and continued margin improvement.
EMR's trailing P/E of 32.2x is 46% above the industrial sector average of 22x, suggesting it is overvalued on past earnings. However, the forward P/E of 19.4x is below the sector average, indicating the market expects significant earnings growth. The PEG ratio of 1.78 suggests the stock is fairly valued relative to its expected growth rate. Compared to its own history, the trailing P/E is near the midpoint of its 5-year range (15x-46x). Overall, the stock appears fairly valued on a forward basis but expensive on a trailing basis, implying that investors are paying for future growth that must materialize.
EMR offers a compelling risk/reward at current levels, with the average analyst target implying 17.4% upside. The forward P/E of 19.4x is below the sector average, suggesting reasonable value. However, the trailing P/E of 32.2x is elevated, and revenue growth is decelerating. For long-term investors with a 3-5 year horizon, the stock could be a good buy given its strong margins and free cash flow. For short-term traders, the recent downtrend and market underperformance pose risks. The biggest downside is a break below the 52-week low of $122.64, which could trigger further selling.
EMR is better suited for long-term investment due to its strong free cash flow, dividend yield of 1.6%, and exposure to secular automation trends. The stock's beta of 1.24 and recent downtrend make it less suitable for short-term trading, as it has underperformed the market by 21.7% over the past year. A minimum holding period of 3-5 years is recommended to allow the growth story to play out and to ride out cyclical volatility. Short-term traders should be cautious given the lack of near-term catalysts and the risk of further downside.